Abstract:Abstract Background: E-cadherin is a tumor suppressor gene involved in cell-cell adhesion, epithelial-to-mesenchymal transitions (EMT) and invasion. Loss of E-cadherin expression is strongly associated with lobular breast cancers, which exhibit single cell patterns of infiltration and are often estrogen receptor positive. We sought to determine if relative risk estimates for 19 established breast cancer susceptibility loci were modified by E-cadherin breast tumor tissue expression. Methods: Case-control analyses included up to 1885 invasive breast cancer cases and 2366 age and site matched controls aged 20–74 years from the Polish Breast Cancer Study (PBCS), a population based case-control study conducted in Poland from 2000–2003. Genotyping of the 19 single nucleotide polymorphisms (SNPs) was performed using TaqMan® assays. Tissue expression of E-cadherin was assessed using immunohistochemical (IHC) staining of tissue microarrays and IHC results were scored as the product of percent positive tumor cells × intensity. Tumors having a score of <10 were classified as E-cadherin low and those with a score ≥10 as E-cadherin high. Polytomous logistic regression models adjusted for age and study site were used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for each breast cancer subtype, defined by E-cadherin expression levels, compared to controls. Case-only data from the PBCS (N = 797) and the Study of Epidemiology and Risk Factors in Cancer Heredity, SEARCH (N = 2155) was used in logistic regression models to test for heterogeneity of SNPs by E-cadherin expression. Results: Three SNPs suggested significant heterogeneity by E-cadherin expression in the PBCS: rs2046210 at 6q25.1(ESR1) [per-allele ORs (95% CI); 1.53 (1.19–1.98) for E-cadherin low tumors and 0.99 (0.86–1.14) for E-cadherin high tumors, P-heterogeneity = 0.002]; rs1045485 at 10p14 (CASP8) [per-allele ORs (95% CI); 0.62 (0.41–0.93) for E-cadherin low tumors and 0.98 (0.81–1.18) for E-cadherin high tumors, P-heterogeneity = 0.04]; and rs11249433 at 1p11.2 (NOTCH2/FCGR1B) [per-allele ORs (95% CI); 1.29 (1.02–1.64) for E-cadherin low tumors and 1.01 (0.88–1.15) for E-cadherin high tumors, P-heterogeneity = 0.06]. Combined case-only analysis of PBCS and SEARCH for these three SNPs showed significant heterogeneity by E-cadherin expression for rs11249433 [Interaction OR (95% CI); 1.19 (1.05–1.36), P-heterogeneity = 0.007] and rs1045485 [Interaction OR (95% CI); 0.69 (0.53–0.90), P-heterogeneity = 0.007]. The association with rs2046210 [Interaction OR (95% CI); 1.12 (0.61–2.03), P-heterogeneity = 0.73] did not remain significant in combined analyses. Conclusion: Our findings provide evidence that associations for breast cancer susceptibility loci vary by E-cadherin tumor tissue expression, which has not been described previously. Specifically, our results suggest that the genetic markers rs11249433 and rs1045485 may preferentially modify risk for tumors with low or absent E-cadherin expression in two independent data sets. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-08-02.

E-cadherin Gene 3'-UTR C/T Polymorphism is Associated with Prostate Cancer.

Genetic Polymorphism in the 3′‐untranslated Region of the E‐cadherin Gene is Associated with Risk of Different Cancers

The E-cadherin (CDH1) |[minus]|160 C|[sol]|A polymorphism and prostate cancer risk: a meta-analysis

Roles of E-Cadherin (cdh1) Genetic Variations in Cancer Risk: A Meta-Analysis

The E-cadherin ( CDH1 ) −160 C/A Polymorphism and Prostate Cancer Risk: a Meta-Analysis

Lack of Evidence for the Association of E-cadherin Gene Polymorphism with Increased Risk or Progression of Prostate Cancer.

Association of CYP2C19*3 Gene Polymorphism with Breast Cancer in Chinese Women.

E-cadherin Promoter Polymorphisms Are Not Associated with the Aggressiveness of Prostate Cancer in Caucasian Patients

A Correlation Study of Single Nucleotide Polymorphisms in Exon 13 of E-cadherin Gene CDH1 with Transitional Cell Carcinoma of the Bladder

The E-cadherin (CDH1) -C160A Polymorphism and Colorectal Cancer Susceptibility: a Meta-Analysis.

Association Between E-cadherin (CDH1) Polymorphisms and Pancreatic Cancer Risk in Han Chinese Population.

Contribution Of The -160c/A Polymorphism In The E-Cadherin Promoter To Cancer Risk: A Meta-Analysis Of 47 Case-Control Studies

The E-Cadherin Gene Polymorphism -160c -> A And Cancer Risk: A Huge Review And Meta-Analysis Of 26 Case-Control Studies

DNA Polymorphisms in Exon 1 and Promoter of the CDH1 Gene and Relevant Risk of Transitional Cell Carcinoma of the Urinary Bladder

CDH1 Gene Rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma.

Prostate stem cell antigen polymorphism rs 2294008 and cancer risk : a meta-analysis

PSCA Rs1045531 Polymorphism and the Risk of Prostate Cancer in a Chinese Population Undergoing Prostate Biopsy

Association of a common genetic variant in prostate stem cell antigen with cancer risk.

Association Of Cdh1 Single Nucleotide Polymorphisms With Susceptibility To Esophageal Squamous Cell Carcinomas And Gastric Cardia Carcinomas

Relationship between an insertion/deletion polymorphism in noncoding region of exon1 of CDH1 Gene and susceptibility of transitional cell carcinoma of the bladder

Abstract P3-08-02: Common Variants at 10p14 and 1p11.2 Display Heterogeneity in Breast Cancer Associations by E-cadherin Tumor Tissue Expression in Two Independent Datasets